Precision logistics for complex therapies

On May 10, 2025, Emily Whitehead will celebrate her 13th anniversary of receiving chimeric antigen T cell receptor (CAR-T) therapy to treat her acute lymphoblastic leukemia, a disease expected to claim 1,400 lives this year in the U.S. alone.1 Emily was the first child ever to receive the treatment and the first patient of any age to receive it for acute lymphoblastic leukemia. To this day, Emily remains cancer-free.

Since then, the field of CAR-T cell therapy, as well as the research and development of cell and gene therapies (CGTs) in general, has skyrocketed. The journey of CGTs, from early inception to current therapeutic successes, has been marked by the necessity of significant logistical and developmental progress. As the breakthroughs in these treatments increase in sophistication, better capabilities are needed in the field.

Patient-specific therapies come with unique logistics that bring added complexity and risk to supply chains. Manufacturing these therapies will continue to require robust supply chain management, stringent quality control and specialized components throughout the network — from facilities and packaging to software and dedicated staffing and expertise.

Precision planning for CGT shipments

Navigating this boom in advanced medicines while maintaining the critical quality attributes (CQAs) of the cells during manufacturing and transport is paramount to the success of the treatment. Maintaining viability and phenotype of the cells throughout the entire supply chain is a significant undertaking — a challenge requiring the oversight of skilled experts, and an understanding of the biology.

The precise requirements of ultrasensitive therapies demand they be stored and delivered within a very narrow window of time, maintained within tight temperatures (ranging from ultracold and cryogenic to controlled room temperature), and with minimal delays. Any disruptions or exposure to extraneous environmental factors, such as vibration, physical shock and ambient temperature, can compromise efficacy and impact delivery to critically ill patients.

To meet the accelerated demand for ultra-sensitive CGTs, precision logistics teams operate around the clock, leveraging advanced technologies, specialized expertise, and expanded network capacity. This integrated approach ensures the timely delivery of ultra-sensitive therapies, minimizing vein-to-vein time and accelerating access to patients. The industry is prioritizing the delivery of these therapies by investing heavily in people, technology, IT infrastructure and facilities to meet the ever-increasing demands of the field. Advancements that support the complex requirements — from operational readiness and quality management to driver excellence and track-and-trace capabilities — are vital to support higher volumes and shorter lead times, a confluence that shifts logistics teams into overdrive to exceed timeframe expectations.

To add to the complexity, patients and hospitals are demanding shorter manufacturing times, and what was previously a two to three week lead time is now being reduced by days and even weeks. With the advent of in vivo gene editing approaches and allogeneic therapy, the vein-to-vein time associated with the bioreactor expansion piece would essentially drop lead times to zero with an off-the-shelf offering, necessitating a more precise logistics and supply chain solution to avoid further bottlenecking the time to patient.

At the same time, the number of regulatory approvals is growing, with 2024 seeing a record number of approvals, along with an increased demand. It is reported that over 34,000 commercially available CAR-T cell therapies have been administered, a number that nearly doubled in the last two years.2 This acceleration has prompted logistics teams to bolster both capabilities and capacity to deliver increased precision for achieving critical timelines, despite the pressure of never-before-seen patient volumes.

Proactive intervention

In the supply chain space, real-time visibility is no longer an optional add-on, but a necessity. It’s become clear that even having state-of-the-art technology, such as real-time data loggers and premier packaging systems, is not sufficient by itself.

A trained and knowledgeable team capable of intervening in the event of a disruption is equally necessary. Modern logistics providers use 24/7 control towers with expert staff following every aspect of a shipment’s journey — an imperative for lowering response times during disruptions, such as traffic delays, labor disputes, weather events, geopolitical strife, or other major disasters. Even when cutting-edge technology is utilized, there still needs to be knowledgeable experts to react swiftly and initiate immediate action using a variety of available pre-determined backup flight and ground transportation options. 

Since these therapies are often highly personalized, they necessitate meticulous tracking and handling of patient-derived materials. Delays or errors may have devastating consequences. To counteract these obstacles, the supply chain requires clear communication, providing timely updates and addressing concerns with all stakeholders involved, including drug manufacturers or sites of care. During the non-interventional stages of a clinical trial, as well as after the therapy is administered, routine collections of samples such as urine and blood may be required, and patients with life-threatening conditions may be unable to have their samples collected without support. Thus, companies with deep clinical expertise often offer home health care services to enable easy access to routine procedures.

Many proponents of cell and gene therapy firmly back the idea these therapies must be made available to patients as earlier lines of therapy. We have seen record approvals from the FDA and other regulatory agencies recently, and these medicines are beginning to demonstrate they are not only safe but, in some cases, more efficacious. This is especially true if used as an earlier line of therapy in extremely sick patients who have exhausted all other therapeutic options. Considering the negative side effects of many major cancer treatment options, we may soon see regulators moving them into first line therapies in the years to come. This requires concerted discussions between regulatory agencies, therapeutic developers, clinicians, and supply chain professionals to ensure patient access is prioritized.

AI technology integration in CGT logistics

The potential benefits of AI and automation are poised to revolutionize our ability to advance the delivery of these personalized treatments. Emerging technologies are analyzing big data from manufacturing, clinical trials and patient outcomes to optimize production processes, predict therapeutic efficacy, and personalize treatment strategies. AI tech also leads to improved efficiency, reduced costs, and consistent product quality. Similarly, AI streamlines supply chain management by predicting demand, optimizing logistics, and ensuring timely delivery of these time-sensitive therapies. Another strength is an AI-powered tool’s ability to aid in vetting patient populations, monitoring and risk assessment, enhancing safety and efficacy. By leveraging AI’s capabilities, CGT delivery may become more efficient, personalized, and, ultimately, more accessible to patients in need.

Though challenges remain in optimizing manufacturing processes for scalability and affordability, experts over the past few years have gained clarity on the necessary steps to ensure consistent product quality and addressing long-term safety and efficacy. Further research into novel vector technologies, target identification, and combination therapies will greatly expand the scope of treatable diseases leading us further into this new age of health care.

Looking forward, the future of CGT hinges on continued collaboration between academia, industry and regulatory bodies. Only through cooperation and transparent communication among key players do we define best practices for streamlining manufacturing, reducing costs, and improving accessibility to bring life-changing benefits for a broader patient population. This commitment to the patient is central to the promise of delivering cell and gene therapies to broader populations worldwide.